Yes. Tirzepatide is a synthetic peptide that activates both GIP and GLP-1 receptors. Its research identifier is LY3298176. The discovery study describes a fatty-acid-modified peptide and reports activity at both receptors. For BulkGLP’s 40 mg research listing and lot documents, see the Tirzepatide peptide product page. Source: Coskun and colleagues, 2018.
Reviewed September 21, 2026. This guide explains compound identity and research terminology. BulkGLP materials are supplied for laboratory research only, not human or veterinary use.
What makes Tirzepatide a peptide?
A peptide contains amino-acid residues connected by peptide bonds. Tirzepatide is a chemically synthesized, modified peptide. “Synthetic” describes how the molecule is produced; it does not mean the molecule stops being a peptide.
“Dual agonist” describes receptor activity. Tirzepatide is one compound with activity at two receptor types, rather than two separately mixed ingredients. GIP means glucose-dependent insulinotropic polypeptide, and GLP-1 means glucagon-like peptide-1. The discovery research evaluated LY3298176 in receptor-signaling and functional assays. Read the discovery study.
Tirzepatide vs. Semaglutide vs. Retatrutide
All three compounds are peptides. Their receptor profiles differ, so their names are not interchangeable in a research record.
| Compound | Receptor profile | Research distinction | Primary source |
|---|---|---|---|
| Tirzepatide / LY3298176 | GIP and GLP-1 | Dual receptor agonist | Coskun et al., 2018 |
| Semaglutide | GLP-1 | Modified GLP-1 analogue | Lau et al., 2015 |
| Retatrutide / LY3437943 | GIP, GLP-1 and glucagon | Triple receptor agonist | Jastreboff et al., 2023 |
Review current formats and batch documentation: Tirzepatide, Semaglutide and Retatrutide.
The number of receptor targets does not provide a universal ranking. A useful laboratory comparison specifies the receptor system, assay conditions, controls and measured endpoint. Published studies characterize the materials used in those studies; they do not certify a supplier’s current product lot.
Understanding the BulkGLP catalog names
BulkGLP lists Tirzepatide 40 mg and Semaglutide 20 mg research vials. Record the compound name, catalog identifier, nominal amount and actual lot number with each order or experiment.
A 40 mg catalog amount describes nominal material per vial. It does not establish a dosing schedule, solution concentration or measured-content result. Consult the lot-specific report for the analytical findings associated with the supplied material.
What to check on a Tirzepatide research listing
- Identity: match the compound name and catalog description to the laboratory’s intended reference material.
- Format and quantity: confirm nominal amount and package configuration.
- Lot documentation: match the vial’s lot to its report and interpret each test according to its method.
- Availability: use the product page for current stock and price.
Start with the Tirzepatide research product and COA reading guide. The batch-report archive provides current and historical records.
Frequently asked questions
Is Tirzepatide a peptide?
Yes. Tirzepatide is a synthetic, modified peptide with activity at GIP and GLP-1 receptors. LY3298176 is its research identifier. Primary research.
Is Tirzepatide the same peptide as Semaglutide?
No. Tirzepatide has a dual GIP/GLP-1 receptor profile, while Semaglutide is a GLP-1 analogue. They are distinct compounds.
How does Retatrutide differ from Tirzepatide?
The cited literature describes Retatrutide activity at GIP, GLP-1 and glucagon receptors. Tirzepatide’s profile covers GIP and GLP-1. They should be identified separately in material and study records.
Does research peptide mean the vial is suitable for medical use?
No. BulkGLP research materials are supplied for laboratory work and are not for human or veterinary use. A compound name or research publication does not change the intended use of the supplied product.
Where are Tirzepatide prices and COAs listed?
The Tirzepatide product page carries the current offer and available lot documentation. Match the supplied material to the relevant report.
Primary research references
- Coskun et al. (2018), discovery and characterization of LY3298176. Molecular Metabolism. DOI: 10.1016/j.molmet.2018.09.009.
- Lau et al. (2015), discovery of Semaglutide. Journal of Medicinal Chemistry. DOI: 10.1021/acs.jmedchem.5b00726.
- Jastreboff et al. (2023), Retatrutide phase 2 study. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972.